Nippon Kayaku launches Infliximab BS I.V. Infusion 100mg “NK”, the Remicade biosimilar, in Japan

December 2, 2014 7:31 AM

Nippon Kayaku Co., Ltd. last week launched the sale of Infliximab BS for I.V. Infusion 100mg “NK” in Japan.

Infliximab BS for I.V. Infusion 100mg “NK” is an infliximab biosimilar drug that plays an important role in treatment of rheumatoid arthritis, inflammatory bowel disease, and other autoimmune diseases. Already marketed in 29 countries including South Korea and parts of Europe, Infliximab BS is the first monoclonal antibody biosimilar to be approved in Japan.

Nippon Kayaku began development of Infliximab BS in November 2010 following the conclusion of an agreement with the Celltrion Group (Incheon, South Korea) for joint development and marketing in Japan. The drug received approval in July 2014.

Infliximab BS for I.V. Infusion 100mg “NK” is the second biosimilar for Nippon Kayaku following the Filgrastim BS Inj. Syringe “NK” first marketed last year. In the field of autoimmune diseases, since 2001 Nippon Kayaku has marketed Saligren® Capsule 30mg, a drug for the treatment of dry-mouth symptoms among patients suffering from Sjögren’s syndrome.

With the marketing of Infliximab BS for I.V. Infusion 100mg “NK”, the company expects to make an even greater contribution to the patients, families, medical professionals dealing with rheumatoid arthritis and inflammatory bowel disease.

Source: Nippon Kayaku press release

Comments are closed

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!